Programmed death ligand 1 (PD-L1) antibody (atezolizumab): Immune checkpoint ligand PD-L1 has been found to increase in invasive lung fibroblasts and drives lung fibrosis in a humanized IPF model in mice. This evidence concerns the gene CD274 and pulmonary fibrosis.